CL
Clearside Biomedical, Inc.
CLSD · NASDAQ
$1.00 -3.85% (-$0.04)
Market Cap $5.23M
P/E Ratio -
Div. Yield -
ROE 55.47%
Piotroski F-Score Weak
2/9Valuation
88 /100
Cheap P/S 1.57x
EV/EBITDA N/A
P/B N/A
Growth
4 /100
Declining Book val. growth 1.67%
Rev. growth 15.16%
FCF growth N/A
Profitability
20 /100
Weak Net margin 780.90%
Op. margin 689.76%
FCF margin 652.96%
Quality
34 /100
Average ROE 55.47%
ROA 223.31%
Asset turnover 0.29x
Debt
71 /100
Low Int. coverage -1.39x
Net debt/EBITDA 0.44x
Current ratio 2.98x
Stability
3 /100
Unstable Rev. volatility 210.51%
EPS volatility 5,142.28%
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o CLSD
Online
O podjetju
Clearside Biomedical, Inc. is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
George Lasezkay
Employees
32
Headquarters
Alpharetta